The makers of Zepbound have introduced a cost-effective self-dosing option for patients, allowing them to save up to 50% on weight-loss injectables.
Eli Lilly's release of single-dose vials of tirzepatide, priced significantly lower than auto-injectors, offers patients the chance to self-administer at a reduced cost.
Jody Dushay noted that for many patients with diabetes, using vials and syringes instead of auto-injectors is a familiar practice, likening it to an 'old school' method.
Despite its potential cost benefits, concerns arise regarding the sourcing of these DIY doses, as many individuals have accessed tirzepatide through questionable means.
[
Collection
]
[
|
...
]